Actively Recruiting
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-27
60
Participants Needed
1
Research Sites
603 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.
CONDITIONS
Official Title
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cancer
- Life expectancy greater than 12 weeks
- Adequate heart, lung, liver, kidney, and blood function
- Availability of high quality vaccine for human use
- Informed consent explained, understood, and signed by patient or guardian with a copy given
You will not qualify if you...
- Previous gene therapy treatment
- Severe viral infections such as HBV, HCV, or HIV
- Known HIV positive status
- Active infectious diseases caused by bacteria, viruses, fungi, or others
- Other severe diseases deemed inappropriate by investigators
- Pregnant or lactating women
- Systemic steroid treatment at or above 0.5 mg prednisone equivalent/kg/day
- Other conditions considered inappropriate by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guanzhou, Guangdong, China, 51260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PhD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here